The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy

Abdul-Majeed S 1 , Mohamed N 2 , Soelaiman IN 3

Affiliations 

  • 1 Department of Life Sciences, School of Pharmacy, International Medical University, No. 126, Jalan 19/155b, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 2 Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Hospital UKM, Jalan Ya'acob Latif, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur, Malaysia
  • 3 Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Hospital UKM, Jalan Ya'acob Latif, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur, Malaysia. Electronic address: imasoel@medic.ukm.my
Life Sci, 2015 Mar 15;125:42-8.
PMID: 25534439 DOI: 10.1016/j.lfs.2014.12.012

Abstract

Statins are competitive inhibitors of HMGCoA reductase and are commonly used as antihypercholesterolemic agents. Experimental studies clearly demonstrate the beneficial effects of statins on bone. Tocotrienols have also been shown to have anti-osteoporotic effects on the skeletal system. This study was conducted to observe the effect of a combination of delta-tocotrienol and lovastatin on structural bone histomorphometry and bone biomechanical strength in a postmenopausal rat model at clinically tolerable doses, and to compare it with the effect of delta-tocotrienol or lovastatin.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications